![Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines? | Bone Marrow Transplantation Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines? | Bone Marrow Transplantation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41409-018-0391-2/MediaObjects/41409_2018_391_Fig1_HTML.png)
Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines? | Bone Marrow Transplantation
Discontinuation of Pneumocystis jirovecii Pneumonia Prophylaxis with CD4 Count <200 Cells/µL and Virologic Suppression: A Systematic Review | PLOS ONE
![Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection - The Lancet Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection - The Lancet](https://www.thelancet.com/cms/attachment/9dcc4036-6394-4bfb-bebe-58e24afdaa93/gr1.jpg)
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection - The Lancet
![IJERPH | Free Full-Text | Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review IJERPH | Free Full-Text | Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review](https://www.mdpi.com/ijerph/ijerph-19-02833/article_deploy/html/images/ijerph-19-02833-g001-550.jpg)
IJERPH | Free Full-Text | Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review
![Table 2 from Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. | Semantic Scholar Table 2 from Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/023cbe2d1c901d0ad9d88b8fb1f01bdc90de6902/4-Table2-1.png)
Table 2 from Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. | Semantic Scholar
![Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. | Semantic Scholar Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4cc1850d68b2e1a3d664497c58c0487eace715dd/63-Table1-1.png)